Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Eller, K; Knoebl, P; Bakkaloglu, SA; Menne, JJ; Brinkkoetter, PT; Grandt, L; Thiem, U; Coppo, P; Scully, M; Haller, MC.
European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis.
Nephrol Dial Transplant. 2022; 37(7): 1229-1234. Doi: 10.1093/ndt/gfac034 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz

Eller Kathrin

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that is caused by severe ADAMTS-13 deficiency. Immune-mediated TTP develops due to autoantibodies against ADAMTS-13, whereas congenital TTP is caused by mutations in the ADAMTS13 gene. Diagnostic possibilities and treatment options in TTP have emerged in recent years, which prompted the International Society on Thrombosis and Haemostasis (ISTH) to publish clinical practice guidelines for the diagnosis and treatment of TTP in 2020. In this article, the European Renal Best Practice Working Group endorsed the ISTH guidelines and emphasizes a number of considerations, including the importance of rapid ADAMTS-13 activity testing, the use of rituximab and anti-von Willebrand factor therapies such as caplacizumab, that enhance the clinical applicability of the guidelines in Europe.

Find related publications in this database (using NLM MeSH Indexing)

ADAMTS13 Protein - administration & dosage

Hemostasis - administration & dosage

Humans - administration & dosage

Purpura, Thrombotic Thrombocytopenic - diagnosis, etiology, therapy

Thrombosis - diagnosis, etiology, therapy

von Willebrand Factor - administration & dosage

Find related publications in this database (Keywords)

AKI

guidelines

plasma exchange

systematic review

thrombotic microangiopathy

© Med Uni Graz • Imprint